Department of Radiological Sciences, University of Rome La Sapienza, Viale Regina Elena 324, Rome 00161, Italy.
Radiology. 2011 May;259(2):574-82. doi: 10.1148/radiol.11100600. Epub 2011 Feb 25.
To determine whether wide-volume perfusion computed tomography (CT) performed with a new generation scanner can allow evaluation of the effects of chemotherapy combined with antiangiogenetic treatment on the whole tumor mass in patients with locally advanced lung adenocarcinoma and to determine if changes in CT numbers correlate with the response to therapy as assessed by conventional response evaluation criteria in solid tumors (RECIST).
Forty-five patients with unresectable lung adenocarcinoma underwent perfusion CT before and 40 and 90 days after chemotherapy and antiangiogenetic treatment. RECIST measurements and calculations of blood flow, blood volume, time to peak, and permeability were performed by two independent blinded radiologists. Pearson correlation coefficient was used to assess the correlation between baseline CT numbers. Baseline and follow-up perfusion parameters of the neoplastic lesions were tested overall for statistically significant differences by using the repeated-measures analysis of variance and then were also compared on the basis of the therapy response assessed according to the RECIST criteria.
Pearson correlation coefficient showed a significant correlation between baseline values of blood flow and blood volume (ρ = 0.48; P = .001), time to peak and permeability (ρ = 0.31; P = .04), time to peak and blood flow (ρ = -0.66; P < .001), and time to peak and blood volume (ρ = -0.39; P = .007). Blood flow, blood volume, and permeability values were higher in responding patients than in the other patients, with a significant difference at second follow-up for blood flow (P = .0001), blood volume (P = .02), and permeability (P = .0001); time to peak was higher in nonresponding patients (P = .012).
Perfusion CT imaging may allow evaluation of lung cancer angiogenesis demonstrating alterations in vascularity following treatment.
确定使用新一代扫描仪进行大容量灌注 CT 是否可以评估化疗联合抗血管生成治疗对局部晚期肺腺癌患者整个肿瘤体积的影响,并确定 CT 数值的变化是否与传统实体瘤疗效评价标准(RECIST)评估的治疗反应相关。
45 例不可切除的肺腺癌患者在化疗和抗血管生成治疗前、治疗后 40 天和 90 天进行了灌注 CT 检查。两位独立的盲法放射科医生进行了 RECIST 测量和血流、血容量、达峰时间和通透性的计算。采用皮尔逊相关系数评估基线 CT 数值之间的相关性。采用重复测量方差分析对肿瘤病变的基线和随访灌注参数进行总体统计学差异检验,然后根据 RECIST 标准评估的治疗反应进行比较。
皮尔逊相关系数显示,血流和血容量的基线值(ρ=0.48;P=.001)、达峰时间和通透性(ρ=0.31;P=.04)、达峰时间和血流(ρ=-0.66;P<.001)、达峰时间和血容量(ρ=-0.39;P=.007)之间存在显著相关性。在有反应的患者中,血流、血容量和通透性值高于其他患者,在第二次随访时血流(P=.0001)、血容量(P=.02)和通透性(P=.0001)有显著差异;无反应患者的达峰时间较高(P=.012)。
灌注 CT 成像可能可以评估肺癌血管生成,显示治疗后血管结构的改变。